Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

Fiona M. Behan(Open Targets), Francesco Iorio(Wellcome Sanger Institute), Gabriele Picco(Wellcome Sanger Institute), Emanuel Gonçalves(Wellcome Sanger Institute), Charlotte Beaver(Wellcome Sanger Institute), Giorgia Migliardi(Candiolo Cancer Institute), Rita Santos(GlaxoSmithKline (United Kingdom)), Yanhua Rao(GlaxoSmithKline (United States)), Francesco Sassi(Candiolo Cancer Institute), Marika Pinnelli(Candiolo Cancer Institute), Rizwan Ansari(Wellcome Sanger Institute), Sarah Harper(Wellcome Sanger Institute), David A. Jackson(Wellcome Sanger Institute), Rebecca McRae(Wellcome Sanger Institute), Rachel Pooley(Wellcome Sanger Institute), Piers Wilkinson(Wellcome Sanger Institute), Dieudonne van der Meer(Wellcome Sanger Institute), David J. Dow(GlaxoSmithKline (United Kingdom)), Carolyn Buser‐Doepner(Open Targets), Andrea Bertotti(Candiolo Cancer Institute), Livio Trusolino(Candiolo Cancer Institute), Euan A. Stronach(Open Targets), Julio Sáez-Rodríguez(RWTH Aachen University), Kosuke Yusa(Open Targets), Mathew J. Garnett(Wellcome Sanger Institute)
Nature
April 10, 2019
10.1038/s41586-019-1103-9
Cited by 1,406Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis